Pneumonia is one of the most prevalent Staphylococcus aureus-mediated diseases, and the treatment of this
infection is becoming challenging due to the emergence of multidrug-resistant S. aureus, especially methicillin-resistant S. aureus (MRSA) strains. It has been reported that LysGH15, the lysin derived from phage GH15, displays high efficiency and a broad lytic spectrum against MRSA and that
apigenin can markedly diminish the alpha-
hemolysin of S. aureus. In this study, the combination
therapy of LysGH15 and
apigenin was evaluated in vitro and in a mouse S. aureus
pneumonia model. No mutual adverse influence was detected between LysGH15 and
apigenin in vitro. In animal experiments, the combination
therapy showed a more effective treatment effect than LysGH15 or
apigenin monotherapy (P < 0.05). The bacterial load in the lungs of mice administered the combination
therapy was 1.5 log units within 24 h after challenge, whereas the loads in unprotected mice or mice treated with
apigenin or LysGH15 alone were 10.2, 4.7, and 2.6 log units, respectively. The combination therapy group showed the best health status, the lowest ratio of wet tissue to dry tissue of the lungs, the smallest amount of total
protein and cells in the lung, the fewest pathological manifestations, and the lowest
cytokine level compared with the other groups (P < 0.05). With regard to its better protective efficacy, the combination
therapy of LysGH15 and
apigenin exhibits therapeutic potential for treating
pneumonia caused by MRSA. This paper reports the combination
therapy of lysin and natural products derived from
traditional Chinese medicine.